Assessment of follow-up for low-grade cytological abnormalities in the national breast and cervical cancer early detection program, 2000-2005

Journal of Lower Genital Tract Disease

Volumn 12, Issue 4, 2008, Pages 300-306

  Benard, Vicki B ^a   Howe, William ^b   Saraiya, Mona ^a   Helsel, William ^b   Lawson, Herschel W ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

Cervical intraepithelial neoplasia; Mass screening; Vaginal tests

Indexed keywords

ADULT; ARTICLE; CANCER DIAGNOSIS; COLPOSCOPY; ENDOMETRIAL DISEASE; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; RACE DIFFERENCE; UTERINE CERVIX CYTOLOGY;

ADOLESCENT; ADULT; CERVIX UTERI; COLPOSCOPY; CONTINUITY OF PATIENT CARE; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 55149117348     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31817e308e     Document Type: Article

References (21)

1. Eltoum IA, Roberson J. Impact of HPV testing, HPV vaccine development and changing screening frequency on national Pap test volume: projections from the National Health Interview Survey (NHIS). Cancer 2007;111:34-40.
2. Jones BA, Davey DD. Quality management in gynecologic cytology using interlaboratory comparison. Arch Pathol Lab Med 2000;124:672-81.
3. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
4. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994;271:1866-9.
5. Ferris DG, Wright TC Jr, Litaker MS, Richart RM, Lorincz AT, Sun XW, et al. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPVDNA testing, orcolposcopy? J Fam Pract 1998;46:125-34.
6. Robertson JH, Woodend B, Elliott H. Cytological changes preceding cervical cancer. J Clin Pathol 1994;47:278-9.
7. Robertson JH, Woodend BE, Crozier EH, Hutchinson J. Risk of cervical cancer associated with mild dyskaryosis. BMJ 1988;297:18-21.
8. Kirby AJ, Spiegelhalter DJ, Day NE, Fenton L, Swanson K, Mann EM, et al. Conservative treatment of mild/ moderate cervical dyskaryosis: long-term outcome. Lancet 1992;339:828-31.
9. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. ASCCP-Sponsored Consensus Conference. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
10. Yabroff KR, Lawrence WF, King JC, Mangan P, Washington KS, Yi B, et al. Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? J Rural Health 2005;21:149-57.
11. Ryerson AB, Benard VB, Major AC. The National Breast and Cervical Cancer Early Detection Program 1991-2002 National Report. Atlanta, GA: Department of Health and Human Services; 2005.
12. Kurman RJ, Solomon D. The Bethseda System for Reporting Cervical/Vaginal Diagnoses. New York: Springer-Verlag; 1993.
13. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. for the Forum Group Members and the Bethesda 2001 Workshop. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
14. Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol 2005;105:1323-8.
15. Saraiya M, Irwin KL, Carlin L, Chen X, Jain N, Benard V, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer 2007;110:1024-32.
16. Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991-1998 (United States). Cancer Causes Control 2001;12:61-8.
17. Eggleston KS, Coker AL, Luchok KJ, Meyer TE. Adherence to recommendations for follow-up to abnormal Pap tests. Obstet Gynecol 2007;109:1332-41.
18. Eggleston KS, Coker AL, Das IP, Cordray ST, Luchok KJ. Understanding barriers for adherence to follow-up care for abnormal Pap tests. J Womens Health (Larchmt) 2007;16:311-30.
19. Wright TC Jr, Massad LS, Dunton CJ, et al, for the 2006 ASCCP-Sponsored Consensus Conference. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007;11:201-22.
20. Stewart FH, Harper CC, Ellertson CE, Grimes DA, Sawaya GF, Trussell J. Clinical breast and pelvic examination requirements for hormonal contraception: current practice vs evidence. JAMA 2001;285:2232-9.
21. Sawaya GF. A 21-year-old woman with atypical squamous cells of undetermined significance. JAMA 2005; 294:2210-8.